Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRINCIPEN vs ACEPHEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ampicillin, a beta-lactam antibiotic, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and interfering with transpeptidation, leading to cell lysis.
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Infections of the respiratory tract (e.g., sinusitis, bronchitis, pneumonia) caused by susceptible organisms,Infections of the genitourinary tract (e.g., urinary tract infections, gonorrhea) caused by susceptible organisms,Infections of the gastrointestinal tract (e.g., typhoid fever, shigellosis) caused by susceptible organisms,Meningitis caused by susceptible organisms (e.g., Listeria monocytogenes, Neisseria meningitidis),Endocarditis (e.g., enterococcal endocarditis) - in combination with an aminoglycoside,Septicemia caused by susceptible organisms,Prophylaxis of bacterial endocarditis in patients undergoing dental or surgical procedures (off-label in some guidelines)
Mild to moderate pain,Fever
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours for moderate infections; severe infections: 500 mg-1 g every 4-6 hours.
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
0.5–1 hour; prolonged to 7–10 hours in renal impairment (creatinine clearance <10 m L/min).
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Ampicillin is partially metabolized by hepatic hydrolysis to penicilloic acid; approximately 90% of an oral dose is excreted unchanged in urine via tubular secretion and glomerular filtration.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Primarily renal (90–100% unchanged) via tubular secretion and glomerular filtration. Minor biliary excretion (<1%).
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
60–80% bound to albumin.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
0.3–0.5 L/kg; indicates limited extravascular distribution.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Oral: 30–50% (variable due to gastric acid lability); IM: 70–85%.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250-500 mg every 6-8 hours; Cr Cl <10 m L/min: 250-500 mg every 12 hours; hemodialysis: 250-500 mg every 12 hours, give dose after dialysis.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No adjustment required for mild to moderate hepatic impairment; caution in severe hepatic disease due to potential for accumulation, but specific Child-Pugh adjustments not established.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Neonates 0-7 days: 50-100 mg/kg/day IV divided every 12 hours; Infants 1-4 weeks: 75-150 mg/kg/day IV divided every 8 hours; Children >1 month: 25-50 mg/kg/day orally divided every 6 hours, or 100-200 mg/kg/day IV divided every 4-6 hours; maximum 12 g/day.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
No specific dose adjustment required; consider age-related renal impairment and adjust based on renal function; monitor for electrolyte disturbances and neurotoxicity.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
None
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported; discontinue therapy if reaction occurs.,Clostridium difficile-associated diarrhea (CDAD) may occur, ranging in severity from mild diarrhea to fatal colitis.,Prolonged use may result in overgrowth of nonsusceptible organisms (e.g., Candida).,Use with caution in patients with renal impairment; dose adjustment may be necessary.,Use with caution in patients with history of allergies (e.g., asthma, hay fever, urticaria) due to increased risk of hypersensitivity.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Hypersensitivity to ampicillin or any other beta-lactam antibiotic (e.g., penicillins, cephalosporins),Infectious mononucleosis (high incidence of maculopapular rash)
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Food decreases absorption; take on an empty stomach. Avoid acidic beverages (e.g., citrus juices) which may degrade the drug. No specific dietary restrictions.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
FDA Pregnancy Category B. Animal studies have not revealed evidence of fetal harm. No adequate, well-controlled studies in pregnant women. However, penicillin-class antibiotics are generally considered low risk. First trimester: No documented teratogenicity. Second and third trimesters: No documented fetal adverse effects. Use only if clearly needed.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Ampicillin is excreted into human breast milk in low concentrations (M/P ratio approximately 0.2-0.3). The American Academy of Pediatrics considers ampicillin compatible with breastfeeding. Potential for alteration of infant gut flora and interference with culture results if febrile. Use caution in infants with known penicillin allergy.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
No clinically significant pharmacokinetic changes requiring dose adjustment in pregnancy. Standard adult dosing is appropriate. For severe infections, higher doses may be needed due to increased volume of distribution and renal clearance, but no specific dose adjustment is routinely recommended.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Principen (ampicillin) is a penicillinase-sensitive penicillin. For empiric coverage, consider local resistance patterns; many E. coli and H. influenzae isolates are resistant. Administer on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption. Monitor for hypersensitivity reactions, especially in patients with penicillin allergy. Use with caution in mononucleosis due to high rash incidence.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Take on an empty stomach, at least 1 hour before or 2 hours after meals.,Complete the full course even if you feel better.,Notify your doctor if you develop a rash, diarrhea, or difficulty breathing.,Do not take if you are allergic to penicillins or cephalosporins.,Store capsules and oral suspension at room temperature; discard unused suspension after 14 days.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRINCIPEN vs ACEPHEN, answered by our medical review team.
PRINCIPEN is a Aminopenicillin Antibiotic that works by Ampicillin, a beta-lactam antibiotic, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and interfering with transpeptidation, leading to cell lysis.. ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRINCIPEN and ACEPHEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRINCIPEN is: 250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours for moderate infections; severe infections: 500 mg-1 g every 4-6 hours.. The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PRINCIPEN and ACEPHEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PRINCIPEN is classified as Category C. FDA Pregnancy Category B. Animal studies have not revealed evidence of fetal harm. No adequate, well-controlled studies in pregnant women. However, penicillin-class antibiotics are. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.